PF 6743649

Drug Profile

PF 6743649

Alternative Names: PF-06743649; PF6743649

Latest Information Update: 12 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gout

Most Recent Events

  • 10 Feb 2015 Pfizer terminates enrolment in phase I trial in Healthy elderly volunteers in USA (NCT02170012)
  • 01 Dec 2014 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT02151617)
  • 10 Nov 2014 Pfizer terminates a phase I trial in Gout in USA (NCT02187029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top